AI is now good enough to change how computational biology teams actually work, but most companies are still adopting it like it’s 2023. Sonia Timberlake, R&D strategy consultant for Timberlake & Maclsaac Biopharma Consulting, speaks with host Eleanor Howe about what’s real: agentic coding, high-throughput data workflows, and the practical limits that still slow teams down. Timberlake digs into benchmarks for capabilities and end-to-end tasks, as well as multimodal chart understanding, source verification, and where human review remains non-negotiable. The conversation also explores beyond AI to what biopharma risks missing, why novel targets still matter, and where investment interest is clustering right now. Plus, tune in to get a preview of Timberlake’s workshop at Bio-IT World Conference & Expo in Boston next month! 

If this helped you think more clearly about AI in drug development and computational biology, subscribe, share the show with a colleague, and leave a review so more builders can find the conversation. 

Links from this episode:  
Workshop: AI Upskilling for Computational Biology Teams
Bio-IT World
BioTeam
Diamond Age Data Science 

Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders.